|Articles|December 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-12-01-2001
  • Volume 0
  • Issue 0

Genetic Test Results Off Limits-For Now

Author(s)Kevin Gopal

London, UK-Insurance companies will be unable to use genetic test results to approve or deny claims for at least the next five years, following a new agreement between the British government and the Association of British Insurers. The move ensures that people can still get insurance coverage whether or not they have had a test.

London, UK-Insurance companies will be unable to use genetic test results to approve or deny claims for at least the next five years, following a new agreement between the British government and the Association of British Insurers. The move ensures that people can still get insurance coverage whether or not they have had a test.

During the next five years, the government will work with the insurance industry to develop a long-term policy. For now, the rules apply to life policies of up to £500,000 and long-term care insurance and income protection of up to £300,000.

Health minister Lord Philip Hunt says, "I recognize that there is public anxiety around the use of genetic test results and insurance, and I welcome this five-year breathing space to work with the industry to get things right. However, if there is evidence of serious and persistent noncompliance by the insurance industry, then the government is prepared to enforce the moratorium, through legislation, if necessary."

Articles in this issue

almost 25 years ago

States Target DTC Advertising

almost 25 years ago

Transparent Moment

almost 25 years ago

GSK at Odds with Activists

almost 25 years ago

Protecting People Everywhere

almost 25 years ago

Opening the Door to Japan

almost 25 years ago

Trade Pact Weakens Patent Protections

almost 25 years ago

EC Questions Dual Pricing

almost 25 years ago

Precious Plasma

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.